Due to the advances in technology, the manufacturers and suppliers are encouraged to seek novel methods for peptide manufacturing, which is bound to improve the production of longer and complex chain of peptides and reduce the cost of production. Moreover, due to the automation of instruments, with improvements in the purification process and reduction in the total waste generated, are the driving factors triggering the growth of the global peptide therapeutics market. However, the synthesis and purification of long peptides is challenging for the manufacturers. Also, the rise in modifications and the addition of more unnatural amino acids have further increased the complications in peptide synthesis. This makes the manufactures of peptides difficult, and therefore the gap between demand and supply is increasing. Also, the manufacturing of peptides is a costly process, which hampers the growth of the global peptide therapeutics market.
Request For Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=189
Haematological disorders are the disorders related to problems in blood and blood components such as red blood cells, white blood cells, platelets, blood vessels, lymph nodes, spleen, bone marrow and the problems related to the proteins involved in bleeding and clotting (haemostasis and thrombosis). Therapeutic peptides are used in the treatment of haematological disorders mentioned above. Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Such type of covalent chemical bonds are formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are differentiated from proteins on the basis of size, and peptides contain 50 amino acids or less approximately.
4 Forecast Highlights on Global Peptide Based Hematological Disorders Therapeutics Market
1. As per the forecast of Fact.MR, the ecallantide segment is slated to touch a value of nearly US$ 120 Mn in the year 2022. This represents a robust CAGR growth during the assessment period of 2017-2022. The ecallantide segment is estimated to account for more than one-fifth of the revenue share of the drug segment by the year 2017 end and is expected to gain in market share by the year 2022 end.
2. As per the forecast of Fact.MR, the retail pharmacies segment will reach a value of nearly US$ 115 Mn in the year 2017. This represents a robust CAGR growth during the forecast period. The retail pharmacies segment is estimated to account for more than one-third of the revenue share of the distribution channel segment in the year 2017 end and is expected to gain market share by the end of the year 2022.
3. As per the forecast of Fact.MR, by the end of 2022, North America peptide based hematological disorders therapeutics market is projected to reach nearly US$ 220 Mn, registering a robust CAGR over the forecast period.
4. As perFact.MR forecasts, the US peptide based hematological disorders therapeutics market is estimated to account for 88.6% revenue share of the global peptide based hematological disorders therapeutics market by 2017 end and is expected to gain in market share by 2022 over 2017.
North America Market Set to Dominate the Global Peptide Based Hematological Disorders Therapeutics Market in Terms of Revenue
The market in North America is set to dominate the global peptide based hematological disorders therapeutics market in terms of value and this trend is projected to sustain itself throughout the assessment period. North America peptide based hematological disorders therapeutics market is the most attractive market, growing at a robust CAGR over the assessment period.
Icatibant Segment Poised to Touch a Value of Nearly US$ 410 Mn in 2022
As per the forecast of Fact.MR, the icatibant segment is expected to reach a value of nearly US$ 410 Mn in the year 2022. This represents a robust CAGR during the forecast period of 2017-2022. Icatibant segment is expected to account for more than three-fourth of the revenue share of the drug segment by the year 2017 and is expected to lose market share by the end of the year 2022.
Browse Full Report with TOC @ https://www.factmr.com/report/189/peptide-based-hematological-disorders-therapeutics-market
Hospital Pharmacies Segment to exhibit a CAGR of 7.4% During the Assessment Period
As per the forecast of Fact.MR, the hospital pharmacies segment is slated to touch a figure of nearly US$ 260 Mn in the year 2022. This represents a CAGR of 7.4% during the assessment period from 2017 till the year 2022. This segment is expected to lose market share by the end of the year 2022. The hospital pharmacies segment is expected to account for more than half of the revenue share of the distribution channel segment by the year 2017.
Competition Tracking
The report also profiles companies that are expected to remain active in the expansion of global peptide based hematological disorders therapeutics market through 2022, which includes Shire plc.
Check Discount @ https://www.factmr.com/connectus/sample?flag=D&rep_id=189
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/